首页> 外文期刊>British Journal of Medicine and Medical Research >Danazol-induced Acute Pulmonary Fibrosis in a Patient with Idiopathic Thrombocytopenic Purpura: Could Anti Fibrosant Therapy be Useful?
【24h】

Danazol-induced Acute Pulmonary Fibrosis in a Patient with Idiopathic Thrombocytopenic Purpura: Could Anti Fibrosant Therapy be Useful?

机译:达那唑诱导的特发性血小板减少性紫癜患者的急性肺纤维化:抗纤溶剂治疗有用吗?

获取原文
获取外文期刊封面目录资料

摘要

Introduction: Danazol is frequently used in the treatment of idiopathic thrombocytopenic purpura (ITP). Very occasionally are described in the elderly fatal respiratory complications related to this drug such as acute pulmonary fibrosis for which no treatment has proven to be effective. Presentation of Case: We describe a case of an old man with ITP treated with danazol who developed a pulmonary fibrosing disease not attributed to any other cause. Damaged lung reversed using an anti fibrosant therapy approved for other types of pulmonary fibrosing diseases. Discussion and Conclusion: Pulmonary fibrosing disease attributed to danazol is a condition refractory to systemic corticosteroids, but as shown in the present case, an anti fibrosant therapy has proven to be a useful alternative and could be recommended in the light of current knowledge.
机译:简介:达那唑经常用于治疗特发性血小板减少性紫癜(ITP)。在这种药物相关的老年人致命性呼吸系统并发症(例如急性肺纤维化)中,很少出现这种情况,但事实证明,这种方法没有有效的治疗方法。病例介绍:我们描述了一位以达那唑治疗的ITP老人的案例,该老人发生了肺纤维化疾病而不是其他原因引起的。使用批准用于其他类型的肺纤维化疾病的抗纤维化疗法,可以使受损的肺扭转。讨论与结论:归因于达那唑的肺纤维化疾病是全身性皮质类固醇难治的疾病,但是如本例所示,抗纤维化治疗已被证明是一种有用的替代方法,可以根据目前的知识予以推荐。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号